

June 16, 2023

To whom it may concern:

Company Name Corporate Representative	TOHO HOLDINGS CO., LTD. Atsushi Udoh, Representative Director, CEO (Prime Market of Tokyo Stock Exchange Securities Code: 8129)
Contact:	Makoto Kawamura, Corporate Officer and General Manager, Corporate Communications and Investor Relations Division (TEL: 81-3-6838-2803)

Notice Regarding Change of Trade Names for 5 Ingredients and 11 Products Manufactured and Sold by the Company

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Yasuyuki Kumada), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has changed the trade names for “5 ingredients and 11 products manufactured and sold by the Company” and launch them under the new names owing to the filing of a new application for substitution today on June 16, 2023 as below.

List of products with changed trade names

Former Trade Names	New Product Name
ADAPALENE GEL “KYOSOMIRAI”	ADAPALENE GEL ”KMP”
IRBESARTAN TABLETS “KYOSOMIRAI” 50mg	IRBESARTAN TABLETS ”KMP” 50mg
IRBESARTAN TABLETS “KYOSOMIRAI” 100mg	IRBESARTAN TABLETS ”KMP” 100mg
IRBESARTAN TABLETS “KYOSOMIRAI” 200mg	IRBESARTAN TABLETS ”KMP” 200mg
FAMCICLOVIR TABLETS “KYOSOMIRAI” 250mg	FAMCICLOVIR TABLETS ”KMP” 250mg
ROSUVASTATIN TABLETS “KYOSOMIRAI” 2.5mg	ROSUVASTATIN TABLETS ”KMP” 2.5mg
ROSUVASTATIN TABLETS “KYOSOMIRAI” 5mg	ROSUVASTATIN TABLETS ”KMP” 5mg
ROSUVASTATIN OD TABLETS “KYOSOMIRAI” 2.5mg	ROSUVASTATIN OD TABLETS ”KMP” 2.5mg
ROSUVASTATIN OD TABLETS “KYOSOMIRAI” 5mg	ROSUVASTATIN OD TABLETS ”KMP” 5mg
ROPINIROLE CR TABLETS “KYOSOMIRAI” 2mg	ROPINIROLE CR TABLETS ”KMP” 2mg
ROPINIROLE CR TABLETS “KYOSOMIRAI” 8mg	ROPINIROLE CR TABLETS ”KMP” 8mg